Eli Lilly and Co. (LLY) emerged as a beacon of optimism last week in a market filled with uncertainty and volatility. Shares ...

In 2024, the European Medicines Agency (EMA) approved lecanemab for the treatment of early Alzheimer's disease in patients without contraindications or risk factors for side-effects. This approval ...

Its donanemab Alzheimer’s drug is seen as a ... These ratings could be tested as Eli Lilly reports earnings tomorrow, especially with investor focus locked on revenue from its blockbuster ...

Eli Lilly has been unable to secure an accelerated FDA approval for its anti-amyloid Alzheimer's disease therapy donanemab based on mid-stage clinical results, but says it remains on track to file ...

The second U.S. drug shown to slow the progression of early Alzheimer's has arrived in Seattle-area clinics. One of the first ...

Eli Lilly has backed away from plans to file Alzheimer's drug donanemab in the first quarter of this year, saying the proposal to limit reimbursement of Biogen's first-to-market Aduhelm has made ...

Lilly did not report any sales of donanemab until the fourth quarter ... for federal health care programs,” the senators wrote to Eli Lilly. “Synapticure is fully independent of Lilly ...

Lilly has an Earnings ESP of -14.61% and a ... Sales of the new Alzheimer’s drug Kisunla (donanemab) are likely to have improved sequentially. Kisunla was approved in China in December 2024 ...